作者
Arnab Chakravarti, Meihua Wang, H Ian Robins, Tim Lautenschlaeger, Walter J Curran, David G Brachman, Christopher J Schultz, Ali Choucair, Marisa Dolled-Filhart, Jason Christiansen, Mark Gustavson, Annette Molinaro, Paul Mischel, Adam P Dicker, Markus Bredel, Minesh Mehta
发表日期
2013/4/1
期刊
International Journal of Radiation Oncology* Biology* Physics
卷号
85
期号
5
页码范围
1206-1211
出版商
Elsevier
简介
PURPOSE
To determine the safety and efficacy of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation for newly diagnosed glioblastoma (GBM) patients.
METHODS AND MATERIALS
Between March 21, 2002, and May 3, 2004, Radiation Therapy Oncology Group (RTOG) 0211 enrolled 31 and 147 GBM patients in the phase 1 and 2 arms, respectively. Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy (RT) and continued post RT for 18 months or until progression. Tissue microarrays from 68 cases were analyzed for EGFR expression.
RESULTS
The maximum tolerated dose (MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs (non-EIAEDs). All patients in the phase 2 component were treated at a gefitinib dose of 500 mg; patients receiving EIADSs could …
学术搜索中的文章
A Chakravarti, M Wang, HI Robins, T Lautenschlaeger… - International Journal of Radiation Oncology* Biology …, 2013